Published in Health Insurance Week, September 3rd, 2006
E. Barrett-Connor and colleagues wrote, "We randomly assigned 10,101 postmenopausal women (mean age, 67.5 years) with CHD or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and followed them for a median of 5.6 years. The two primary outcomes were coronary events (i.e., death from coronary causes, myocardial infarction, or hospitalization for an acute coronary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.